Related Experiment Videos
Urinary metabolites of halothane in man
Anesthesiology
|October 1, 1975
Summary
Researchers identified key urinary metabolites of halothane (2-bromo-2-chloro-1,1,1-trifluoroethane), revealing reactive intermediates. This aids understanding of halothane metabolism and potential liver toxicity.
Area of Science:
- Pharmacology
- Toxicology
- Analytical Chemistry
Background:
- Halothane (2-bromo-2-chloro-1,1,1-trifluoroethane) is an anesthetic agent.
- Understanding halothane metabolism is crucial for assessing its safety and potential hepatotoxicity.
Purpose of the Study:
- To investigate and identify the nonvolatile urinary metabolites of halothane in humans.
- To elucidate the metabolic pathways and reactive intermediates involved in halothane biotransformation.
Main Methods:
- Radioactive labeling (14C-halothane) of the anesthetic agent.
- Advanced separation techniques: chemical extraction, electrophoresis, ion-exchange chromatography, HPLC, and GC.
- Structure identification using nuclear magnetic resonance (NMR) and mass spectrometry (MS).
Main Results:
- Three major halothane metabolites were identified: trifluoroacetic acid, N-trifluoroacetyl-2-aminoethanol, and N-acetyl-S-(2-bromo-2-chloro-1,1-difluoroethyl)-L-cysteine.
- Presence of both ethanolamide and cysteine conjugates suggests reactive intermediates.
- Unidentified radioactive peaks indicate other minor metabolites.
Conclusions:
- The identified urinary metabolites provide insights into halothane metabolism.
- The formation of reactive intermediates is implicated in halothane-induced hepatotoxicity.
- These findings contribute to understanding the mechanisms underlying halothane's adverse effects.